DDInter1259 DDInter492
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340]
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) resembles {v} (Compound) Rosoxacin
Rosoxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) binds {v} (Gene) TDO2
TDO2 {u} (Gene) is bound by {v} (Compound) Tolmetin
Tolmetin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may lead to a major life threatening interaction when taken with {v} Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pramlintide
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deflazacort
Nalidixic acid {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deflazacort
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may lead to a major life threatening interaction when taken with Deflazacort
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may lead to a major life threatening interaction when taken with Deflazacort
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Nalidixic acid (Compound) resembles Rosoxacin (Compound) and Rosoxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may lead to a major life threatening interaction when taken with Deflazacort
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nalidixic acid (Compound) binds TDO2 (Gene) and TDO2 (Gene) is bound by Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nalidixic acid (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort